nC-001

nephCentric · Phase 2 active Small molecule

At a glance

Generic name	nC-001
Sponsor	nephCentric
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2a Study for PK/PD of nC-001 (PHASE2)
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

nC-001 CI brief — competitive landscape report
nC-001 updates RSS · CI watch RSS
nephCentric portfolio CI